Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 631 across all filing types
Latest filing 2026-05-05 Regulatory Filings
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Udzielenie patentu w Kanadzie - Content (PL)
Regulatory Filings
2026-05-05 Polish
Zawarcie umowy na badania stabilności przyszłego wyrobu medycznego na trudno gojące się rany - Content (PL)
Regulatory Filings Classification · 75% confidence The document is a current update notice (“raport bieżący”) published in the ESPI system, detailing the signing of a research contract and project milestones. It is not an earnings release, quarterly/annual report, capital change, or other specific category but rather a general regulatory announcement of a material event. This fits the Regulatory Filings (RNS) category.
2026-04-13 Polish
Zakończenie opracowania i walidacji metod analizy przyszłego wyrobu medycznego na trudno gojące się rany - Content (PL)
Regulatory Filings Classification · 80% confidence The document is a ‘raport bieżący’ (current report) under the Polish ESPI system announcing the completion of a project milestone (analytical method development/validation) and future project stages. It is a corporate update on R&D progress rather than a financial results release, regulatory change, share issue, or formal report like an annual or interim report. It does not include detailed financial tables or request shareholder votes. It therefore falls into the general fallback category for miscellaneous regulatory filings (RNS).
2026-03-24 Polish
Zakończenie oceny skuteczności 1-MNA w łuszczycy - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement (raport bieżący) issued by PHARMENA S.A. regarding the completion of a clinical research project (1-MNA for psoriasis). It provides an update on the status of a specific business project and its potential impact on the company's future, which is a standard disclosure for publicly traded companies. Since it does not fit into specific categories like financial reports, dividends, or director dealings, it falls under the general regulatory filing category.
2026-03-05 Polish
Oświadc zenie Rady Nadzorc zej ws. audytora i komitetu audytu za 2025
Regulatory Filings
2026-02-24 Polish
Oświadczenie Ocena Rady Nadzorczej za badania SF za 2025 (Sprawozdanie z działalności RN)
Regulatory Filings
2026-02-24 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.